Recent developments
AI summary of recent coverageRecent coverage has focused on Michael Bailey's appointment as chief executive officer of Verastem Oncology, effective January 1, 2027, succeeding retiring CEO Daniel Paterson. The announcement coincided with the company's pricing of a $250 million offering, with stock rising in pre-market trading.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Michael Bailey, it will appear here — and tie into the news timeline.
Michael Bailey: FAQ
- What company does Michael Bailey lead?
- Michael Bailey is CEO of Verastem, Inc..